Innovent Biologics, Inc., a world-class biopharmaceutical company, announced that results of higher-dose cohorts in a phase 1b study of mazdutide (IBI362), a glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist, in Chinese participants with overweight or obesity have been published online in eClinicalMedicine. Professor Linong Ji and Professor Leili Gao from Peking University People
